According to Vericel 's latest financial reports the company's current revenue (TTM) is $0.19 B. In 2022 the company made a revenue of $0.16 B an increase over the years 2021 revenue that were of $0.15 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.19 B | 20.17% |
2022 | $0.16 B | 5.24% |
2021 | $0.15 B | 25.77% |
2020 | $0.12 B | 5.37% |
2019 | $0.11 B | 29.71% |
2018 | $90.85 M | 42.13% |
2017 | $63.92 M | 17.54% |
2016 | $54.38 M | 6.28% |
2015 | $51.16 M | 77.69% |
2014 | $28.79 M | 151457.89% |
2013 | $0.01 M | -9.52% |
2012 | $0.02 M | 16.67% |
2011 | $0.01 M | |
2009 | $0.21 M | -46.8% |
2008 | $0.4 M | -31.65% |
2007 | $0.59 M | -28.26% |
2006 | $0.82 M | 28.37% |
2005 | $0.64 M | -45.66% |
2004 | $1.18 M | 4.77% |
2003 | $1.13 M | 56.71% |
2002 | $0.72 M | 8.23% |
2001 | $0.66 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Royalty Pharma RPRX | $2.35 B | 1,092.08% | ๐ฌ๐ง UK |
Neogen NEOG | $0.92 B | 370.46% | ๐บ๐ธ USA |